Tenpoint Therapeutics won FDA approval for Yuvezzi, the first dual‑agent eye drop for adult presbyopia combining carbachol and brimonidine, and simultaneously closed financing commitments totaling up to $235 million (equity and debt). The approval establishes a differentiated commercial product in a crowded topical presbyopia market and the financing provides launch capital and working capital for commercialization and distribution. Regulatory clearance plus substantive financing de‑risks Tenpoint’s go‑to‑market plan and positions the company to compete with incumbent and emerging topical treatments. For investors, the package demonstrates a playbook where regulatory milestones are tightly coupled with capital raises to accelerate commercialization in specialty ophthalmic indications.